The plasma fractionation market has experienced remarkable growth, achieving an impressive Compound Annual Growth Rate (CAGR) of 8%. As of 2023, the market has reached a significant value of US$ 52.64 billion by 2030. This growth can be attributed to the increasing demand for plasma-derived products in various medical applications, advancements in fractionation technologies, and rising awareness about the benefits of plasma-based therapies. The market's expansion is expected to continue, driven by ongoing research and development efforts in the field of biotechnology and the growing prevalence of chronic diseases necessitating plasma-derived treatments.
The report "Global Plasma Fractionation Market, By Product Type (Albumin, Immunoglobulins, Coagulation factor concentrates, and Others), By Application (Neurology, Hematology, Immunology, Critical Care, and Others), By End User (Hospitals and Clinics, Clinical Research Laboratories, and Academic Institutes), and Region - Global Forecast to 2030"
Sample link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/537
Key Highlights:
• In December 2017, BioLife Plasma Services L. P. had files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing immunology franchise.

Analyst view:
From an analyst's perspective, the performance of the global plasma fractionation market with an 8% CAGR and reaching a value of US$ 52.64 billion by 2030 is a positive indicator of the industry's growth and potential. The steady CAGR reflects a robust and sustainable market demand for plasma-derived products, driven by a variety of factors.Firstly, the increasing prevalence of chronic diseases, such as immune disorders, hemophilia, and neurological conditions, has heightened the demand for plasma-based therapies and treatments. Plasma-derived products are vital in managing these conditions, thereby contributing to the market's expansion.Secondly, advancements in fractionation technologies have improved the efficiency and scalability of plasma fractionation processes, resulting in higher yields of high-quality plasma-derived products. These technological improvements have enhanced manufacturing capabilities, making these therapies more accessible to patients worldwide.
Composition view:
The prominent player operating in the global plasma fractionation market includes CSL Plasma, Inc., Grifols S.A., BioLife Plasma Services L. P., Octapharma Plasma, Inc., Kedrion S.p.A, Bio Product Laboratory Ltd., LFB S.A., Biotest Pharmaceuticals Corporation, Japan Blood Products Organization, and China Biologic Products Holdings, Inc.
To know more
Contact Us:
Sales
Prophecy Market Insights
U.S. 1 860 531 2574
RoW: 917775049802
Email- [email protected]
Website- www.prophecymarketinsights.com
Blog- www.prophecyjournals.com